Rheumatoid Arthritis
Expert Commentary and Journal Scans: February 2021
Dr. Jayatilleke: Research provides credible evidence for an increase in dementia in RA patients with CVD
- Temporomandibular pain more common in individuals at risk for RA
- RA: Treat-to-target strategy improves likelihood of reaching treatment targets
- MRI-targeted treatment strategy: A positive predictor for remission in RA
- VTE risk higher in patients with RA
- Hydroxychloroquine use not linked to increased risks for psychiatric events
- Increased risk of RA in patients with endometriosis
- Efficacy of filgotinib in patients with RA with limited or no methotrexate exposure
- CVD and CV risk factors linked to increased dementia risk in patients with RA
- Elevated disease activity, cytokine levels linked to diabetes risk in RA
- Hydroxychloroquine use not linked to heart failure risk in patients with RA
Expert Commentary and Journal Scans: January 2021
Dr. Jayatilleke: These findings could potentially greatly alter RA treatment algorithms
- Early treatment response may predict sustained DMARD-free remission in RA
- Baricitinib favorable for long-term treatment of moderate to severe RA
- ANA measurement before TNFi therapy could help predict treatment failure in RA
- Perceived distress linked to inflammatory arthritis among at-risk individuals
- Gut microbiome influences response to methotrexate in new-onset RA patients
- Prognostic factors for short-term mortality in RA patients admitted to ICU
- Tocilizumab + methotrexate vs. tocilizumab alone for preventing radiographic progression in RA
- Oral glucocorticoids plus PPIs raise osteoporotic fracture risk in patients with RA
- RA: Depression tied to greater disease activity and pain
- Inflammation of juxta-articular soft tissues could be an early feature of RA